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Abstract 
Aims: Individuals with type 2 diabetes (T2DM) and mixed dyslipidaemia represent a 
high-risk and difficult-to-treat population. ODYSSEY DM-DYSLIPIDEMIA 
(NCT02642159) compared alirocumab, a proprotein convertase subtilisin-kexin type 
9 inhibitor, with usual care (UC) in individuals with T2DM and mixed dyslipidaemia 
not optimally managed by maximally-tolerated statins. 
Materials and Methods: UC options (no additional lipid-lowering therapy; 
fenofibrate; ezetimibe; omega-3 fatty acid; nicotinic acid) were selected prior to 
stratified randomization to open-label alirocumab 75 mg every 2 weeks (Q2W; with 
increase to 150 mg Q2W at Week [W]12 if W8 non-high-density lipoprotein 
cholesterol [non-HDL-C] was ≥2.59 mmol/L [100 mg/dL]) or UC for 24 weeks. 
Primary efficacy endpoint was percentage change in non-HDL-C from baseline to 
W24.  
Results: The randomized population comprised 413 individuals (409 intention-to-
treat; 412 safety). At W24, mean non-HDL-C reductions were superior with 
alirocumab (-32.5% difference vs UC; 97.5% confidence interval: -38.1 to -27.0; 
P<.0001). Overall, 63.6% of alirocumab-treated individuals were maintained on 
75 mg Q2W. Alirocumab also reduced low-density lipoprotein cholesterol (-43.0%), 
apolipoprotein B (-32.3%), total cholesterol (-24.6%), and LDL particle number (-
37.8%) at W24 vs UC (all P<.0001). Consistent with the overall trial comparison, 
alirocumab reduced non-HDL-C to a greater degree within each UC stratum at W24. 
Incidence of treatment-emergent adverse events was 68.4% (alirocumab) and 66.4% 
(UC). No clinically meaningful effect on glycated hemoglobin, or change in number of 
glucose-lowering agents, was seen.  
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Conclusions: In individuals with T2DM and mixed dyslipidaemia on maximally 
tolerated statin, alirocumab showed superiority in non-HDL-C reduction vs UC and 
was generally well tolerated. 
Key words: PCSK9, type 2 diabetes, mixed dyslipidaemia, non-HDL-C 
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1. INTRODUCTION 
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity 
and mortality among individuals with type 2 diabetes mellitus (T2DM).1 The reasons 
are likely multifactorial but a relevant contributory factor may be the greater 
prevalence of mixed dyslipidaemia, which is characterized by elevated triglycerides 
(TGs) and thus elevated triglyceride-rich lipoprotein (TRL) and TRL cholesterol as 
well as low levels of high-density lipoprotein cholesterol (HDL-C).2 Mixed 
dyslipidaemia in T2DM might not be detected with measurement of LDL-C levels, as 
LDL-C may remain within a normal range.3 Non-high-density lipoprotein cholesterol 
(non-HDL-C; easily calculated by subtracting HDL-C from total cholesterol), accounts 
for the sum of all atherogenic lipoproteins (low-density lipoprotein cholesterol [LDL-
C], intermediate-density lipoproteins (IDL), very-low density lipoproteins (VLDL), 
VLDL remnants, chylomicron remnants, and lipoprotein a [Lp(a)]) and has been 
suggested to be a better indicator of cardiovascular (CV) risk than LDL-C among 
individuals with elevated TGs, including individuals with dyslipidaemia.3-5 Populations 
with mixed dyslipidaemia also have qualitative changes in low-density lipoprotein 
(LDL) particles, with a higher number of smaller, more dense LDL particles; these  
are believed to be more atherogenic than larger, more buoyant particles.2  
Lipid lowering therapy (LLT) with statins increases the clearance of atherogenic 
lipoproteins and thus reduces plasma cholesterol levels principally through 
reductions in LDL-C.6 This results in a significantly lower risk of ASCVD with the 
proportional benefit related to the absolute reduction in LDL-C.7 Other therapeutic 
approaches that further increase clearance of atherogenic lipoproteins include 
ezetimibe8 and the inhibitors of proprotein convertase subtilisin-kexin type 9 
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(PCSK9), alirocumab9 and evolocumab.10 Adding ezetimibe or evolocumab to statin 
significantly reduces CV events (the CV outcomes study with alirocumab 
[NCT01663402] is ongoing).11,12 However, no previous studies prospectively 
evaluated PCSK9 inhibition in individuals with diabetes and mixed dyslipidaemia or 
compared different therapeutic options among individuals with elevated TGs despite 
maximally tolerated statin therapy, an important consideration given the “real-world” 
clinical uncertainty around potential therapeutic agents which principally reduce 
either the synthesis of TRL particles (fibrates), lipolysis of TGs (omega-3-fatty acids), 
clearance of atherogenic lipoproteins (ezetimibe), or a combination of these 
mechanisms (nicotinic acid). 
The ODYSSEY DM-DYSLIPIDEMIA trial was designed to address these clinical 
uncertainties and assessed the efficacy and safety of alirocumab vs usual lipid-
lowering care (UC) stratified by an investigator’s pre-defined option for add-on 
therapy (fenofibrate, omega-3-fatty acids, ezetimibe, nicotinic acid or no additional 
LLT) to maximally tolerated statins among individuals with T2DM at high ASCVD risk 
who had mixed dyslipidaemia and in whom non-HDL-C was not adequately 
controlled (≥ 2.59 mmol/L [≥100 mg/dL]). The primary endpoint (not used in previous 
randomized studies) was the difference in the percentage change from baseline in 
non-HDL-C between alirocumab and UC (overall, i.e. all options). A pre-specified 
analysis compared the superiority of alirocumab vs fenofibrate (recommended in 
guidelines for treating individuals with elevated TGs4,5). 
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2. MATERIALS AND METHODS 
2.1. Study design 
ODYSSEY DM-DYSLIPIDEMIA (NCT02642159) was a phase 3b/4, randomized, 
open-label, parallel group, multi-centre trial. The trial was conducted at 110 sites in 
14 countries; screening started in March 2016 and recruitment was completed in 
September 2016. The study design and methods have been published.13 Brief 
methods are summarized below and further details are provided in the 
Supplementary Appendix. 
The trial was conducted in accordance with the ethical principles laid down by 
the 18th World Medical Assembly (Helsinki, 1964) and all applicable amendments 
laid down by the World Medical Assemblies, and the International Conference on 
Harmonisation guidelines. The trial protocol was approved by the relevant 
institutional review boards or independent ethics committees, and all participating 
individuals provided written informed consent. 
2.2. Trial participants 
The trial included individuals (aged ≥18 years) with T2DM and mixed dyslipidaemia 
whose non-HDL-C was not adequately controlled despite stable maximally tolerated 
statin dose for ≥4 weeks prior to screening visit, without other LLTs, and who had 
either a documented history of ASCVD or at least 1 additional CV risk factor. Study 
participants had to have a glycated hemoglobin (A1C) of <9%; changes to 
antihyperglycaemic medications were to be limited and made only in circumstances 
of clinical need for the duration of the study. 
This article is protected by copyright. All rights reserved.
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Mixed dyslipidaemia was defined as non-HDL-C ≥2.59 mmol/L (≥100 mg/dL) 
and TGs ≥1.70 mmol/L (150 mg/dL) (but <5.65 mmol/L [500 mg/dL]) at the screening 
visit. The maximally tolerated dose of statin was based on the judgement of the 
investigator. Individuals with documented statin intolerance (as judged by the 
investigator) and therefore not receiving statin therapy could also be enrolled. 
ASCVD was defined as coronary heart disease, peripheral arterial disease or 
ischaemic stroke. Full inclusion and exclusion criteria have been reported 
previously.13 
2.3. Study procedures 
Following up to a 3-week screening period, investigators selected before 
randomization the most appropriate choice from a range of 5 therapeutic options 
based on their usual clinical practice, namely not to add any LLT, or to add 1 of the 
following: ezetimibe, fenofibrate, omega-3 fatty acid formulation or nicotinic acid. 
Participants were randomised in a 2:1 ratio to receive on top of maximally tolerated 
statin (or no statin if intolerant) either open-label alirocumab or UC for 24 weeks. 
Randomization was stratified by the UC option selected by the investigator prior to 
randomization. 
Alirocumab was initiated at a dose of 75 mg every 2 weeks (Q2W), with blinded 
dose increase to 150 mg Q2W at Week 12 if Week 8 non-HDL-C was ≥2.59 mmol/L 
(≥100 mg/dL), henceforth referred to as “alirocumab 75/150 mg Q2W”.  
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2.4. Endpoints and assessments 
The primary efficacy endpoint was the percentage change in non-HDL-C from 
baseline to Week 24, analysed using an intention-to-treat approach. Further details 
on secondary endpoints and laboratory and safety assessments are given in the 
Supplementary Appendix. 
2.5. Statistical analysis 
The primary efficacy endpoint was analysed using a mixed-effect model with 
repeated measures approach to account for missing data. Further information on 
analysis methods are presented in the Supplementary Appendix. 
This article is protected by copyright. All rights reserved.
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3. RESULTS 
3.1. Participating individuals 
Eligible individuals were allocated to UC options by the investigator prior to 
randomization, and were subsequently randomized within each stratum to either 
alirocumab or UC option with a 2:1 ratio (Figure 1). A total of 413 individuals were 
randomized to alirocumab (n=276) or UC (n=137). Median daily doses of UC 
treatments are given in Table S1.  
Baseline characteristics and lipid parameters were generally similar regardless 
of treatment allocation (Table 1; Table S2). At baseline, 84.0% of individuals in the 
alirocumab group and 76.6% in the UC group were receiving statin therapy (of these, 
46.3% [alirocumab] and 36.2% [UC] were on high-intensity statin). Treatment groups 
included 34.4 and 34.3% of individuals with a history of ASCVD and 65.6 and 65.7% 
without ASCVD but with additional CV risk factors in the alirocumab and UC groups, 
respectively (Table 1). 
3.2. Lipid parameters 
The least-squares mean (standard error [SE]) percentage change from baseline to 
Week 24 in non-HDL-C was –37.3 (3.0)% with alirocumab and –4.7 (3.3)% with UC 
(–32.5% difference vs UC; P < .0001; 97.5% confidence interval: –38.1 to –27.0; 
Figure 2A). Alirocumab also significantly lowered levels of measured LDL-C, 
apolipoprotein (Apo) B, total cholesterol and lipoprotein (a) [Lp(a)] vs UC (all P < 
.0001, Figure 2A). Non-HDL-C and measured LDL-C reductions were observed from 
the first measured time point at Week 8 and maintained through the 24-week 
treatment period (Figure S1).TG levels were decreased in both arms at Week 24 
with no significant difference between alirocumab (–13.0%) vs UC (–8.8%; Figure 
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2A). As a result of the hierarchical testing procedure used, P-values from 
subsequent testing of secondary endpoints are nominal only. At Week 24, 
alirocumab treatment resulted in improvements from baseline (nominal P-value < 
.025 vs UC) in HDL-C, and LDL particle number and size (Figure 2A). Results for 
fenofibrate stratum and other individual UC strata were similar to the overall analysis 
(Figure 2B–E); due to small patient numbers data were not analysed for the nicotinic 
acid stratum. Similar results to Week 24 were seen at Week 12, when all individuals 
in the alirocumab arm were receiving the 75 mg dose (Figure S2). In the alirocumab 
group, 75 mg Q2W dose was maintained in 63.6% of individuals after Week 12.  
At Week 24, more than two-thirds of alirocumab-treated individuals achieved 
levels of non-HDL-C <2.59 mmol/L (<100 mg/dL), measured LDL-C <1.81 mmol/L 
(<70 mg/dL) and ApoB <80 mg/dL (Figure 3). In addition, a greater proportion of 
individuals in the alirocumab group vs UC achieved a reduction in LDL-C from 
baseline of ≥50% (55.2% vs 3.8%).  
Results were consistent across various subgroups analysed (Figure S3, 
Supporting Information). 
3.3. Free and total PCSK9 
In the alirocumab group, free PCSK9 levels changed by –43.3% and –60.6% at 
Week 12 and Week 24, respectively (UC: +18.2% and +11.8%, respectively; Figure 
4). Total PCSK9 levels changed by +357.6% at Week 12 and +413.3% at Week 24 
in the alirocumab group (UC: +13.9% and +10.8%, respectively; Figure 4). 
Corresponding data within individual UC strata are also shown in Figure 4. 
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3.4. Diabetes-related endpoints 
Mean levels of A1C and fasting plasma glucose (FPG) during the study are shown in 
Figure S4. Mean (SE) absolute change from baseline in A1C at Week 24 was +0.24 
(0.04)% (alirocumab group) and +0.19 (0.05)% (UC group; P = . 4923 vs UC). Mean 
(SE) absolute change in FPG from baseline at Week 24 was +0.32 (0.13) mmol/L 
and –0.01 (0.17) mmol/L in the alirocumab and UC groups, respectively (P = .1215 
vs UC); corresponding values for FPG were +5.70 (2.25) and –0.10 (3.07) mg/dL for 
alirocumab and UC, respectively. The median total number of glucose-lowering 
treatments received remained stable over time with no change between baseline and 
Week 24 (Table S3). 
3.5. Safety  
The percentage of individuals who experienced any treatment-emergent adverse 
events (TEAEs), treatment-emergent serious adverse events and TEAEs leading to 
discontinuation was comparable between the alirocumab and UC groups (Table S4).  
TEAEs occurring in ≥2% of individuals were reported at generally similar 
frequencies in the alirocumab and UC groups, with some TEAEs occurring at higher 
frequency in the alirocumab vs UC group and vice versa; urinary tract infection 
(alirocumab: 5.8%; UC: 3.6%) and diarrhoea (alirocumab: 5.1%; UC: 6.6%) were the 
most common TEAEs (Table S5).  
In total, 3.0% (n = 8) of individuals receiving alirocumab and 0.8% (n = 1) of 
those receiving UC had low-titre persistent anti-drug antibodies. At Week 12, 0.7% 
(n = 2) of individuals in the alirocumab group demonstrated positive neutralizing 
antidrug antibodies; none were observed at Week 24. In the UC group, no 
neutralizing anti-drug antibodies were observed.    
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4. DISCUSSION 
ODYSSEY DM-DYSLIPIDEMIA is the first dedicated study of a PCSK9 inhibitor to 
evaluate efficacy and safety vs UC among individuals with T2DM and mixed 
dyslipidaemia and elevated non-HDL-C levels, despite maximally tolerated statin 
therapy, and the first randomized trial to use non-HDL-C as the primary endpoint. 
The pragmatic design of this study with the choice of UC (in addition to maximally 
tolerated statin therapy) based on the investigator’s pre-defined option allows for the 
first time a direct comparison with multiple therapeutic alternatives to alirocumab and 
their effects on non-HDL-C as well as a range of lipoprotein markers believed to be 
causally related to ASCVD. 
Alirocumab demonstrated superiority from baseline to Week 24 in reducing non-
HDL-C (by 32.5%), ApoB (32.3%), Lp(a) (27.4%), total cholesterol (24.6%) and 
measured LDL-C (43.0%) vs UC. Alirocumab was not superior to UC in reducing 
TGs and, due to the hierarchical nature of testing, the significant increase in HDL-C 
(+6.2%) and significant reductions in LDL particle number (–37.8%) and LDL particle 
size (–1.8%) relative to UC should be considered nominal. Moreover, in this study, 
66.9% of alirocumab-treated individuals reached non-HDL-C <2.59 mmol/L (100 
mg/dL; 17.7% with UC) and 70.8% achieved LDL-C <1.81 mmol/L (70 mg/dL) vs 
16.3% with UC. 
Alirocumab was also superior to fenofibrate in reducing non-HDL-C (33.3% vs 
fenofibrate), ApoB (35.2%), Lp(a) (22.8%), total cholesterol (25.3%) and measured 
LDL-C (55.7%). At Week 24, the percentage change from baseline in the fenofibrate 
group was equivalent to the alirocumab group in lowering TG and raising HDL-C 
when added to maximally tolerated statin therapy. However, participants in this study 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
had moderately elevated TGs (median baseline TGs of ~2.4 mmol/L [~210 mg/dL]), 
and conclusions cannot be extrapolated to those with more severely elevated 
triglycerides (>5 mmol/L) who were excluded from the study. Nominally greater 
reductions from baseline to Week 24 in LDL particle number (42.4%) and LDL 
particle size (3.1%) favoured alirocumab over fenofibrate. Furthermore, at Week 24, 
65.2% of patients achieved non-HDL-C <2.59 mmol/L (<100 mg/dL) and 71.9% LDL-
C <1.81 mmol/L (<70 mg/dL) with alirocumab vs 10.1% and 17.5%, respectively, 
with fenofibrate. Directionally concordant results were observed favouring 
alirocumab vs no LLT, omega-3 fatty acids or ezetimibe where sample size allowed 
such comparisons.  
The present study also offers novel insights into the potential mechanisms 
behind changes in different lipid parameters when other LLTs are added to statins 
and the potential impact of these differential changes on the putative likelihood of 
future ASCVD. In the overall UC group, mean total and free PCSK9 concentrations 
changed by +10.8% and +11.8%, respectively, at Week 24 compared with baseline; 
larger increases were seen in the fenofibrate group and also (to a lesser extent) in 
the ezetimibe group, in line with previous observations that treatment with these 
LLTs increase PCSK9 levels.14,15 Omega-3 fatty acids appeared to have a negligible 
effect on PCSK9 levels. The increases in PCSK9 levels in the overall UC group were 
associated with only modest reductions from baseline to Week 24 in ApoB (–1.6%) 
and LDL particle number (–3.9%), and increase in LDL particle size (0.3%) and 
therefore modest reductions in non-HDL-C (–4.7%) and measured LDL-C (–0.3%), 
despite an 8.8% reduction in TGs and an 8.2% increase in HDL-C. In contrast, at 
Week 24 total PCSK9 levels increased among alirocumab-treated patients by 
+413.3% and free PCSK9 decreased by –60.6%, reflecting that most circulating 
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PCSK9 was bound to alirocumab. This in turn reduced ApoB, non-HDL-C and LDL 
particle number by approximately one third and measured LDL-C by about two fifths, 
compared with the more modest reductions in the UC group, and resulted in a 
greater proportion (66.9%) of individuals achieving non-HDL-C <2.59 mmol/L 
(<100 mg/dL) with alirocumab vs the addition of UC to statins (17.7%). Taken 
together, these results demonstrate the significant impact on clearance of 
atherogenic particles by targeting PCSK9 for inhibition with alirocumab compared 
with the different modes of actions of the UC therapies. Conversely, extracellular 
PCSK9 inhibition with alirocumab does not appear to substantially affect TG 
metabolism, although reductions in TGs with alirocumab were similar to those 
observed with fenofibrate. 
Based on post hoc data from the ACCORD trial or from meta-analyses of fibrate 
trials,16,17 many clinicians add fibrates to statins in individuals with high TGs or high 
TGs/low HDL-C. However, in the present pre-specified analyses we demonstrate 
that the addition of fenofibrate to statins results in little or no reduction in atherogenic 
lipoproteins and hence a trivial reduction in their cholesterol cargo, despite 
favourable but clinically modest changes in TG and HDL-C. These data underscore 
the importance of therapeutic approaches that increase the clearance of atherogenic 
lipoproteins rather than other currently available therapies (apart from statins) that 
target either synthesis or lipolysis of TG, but which have little impact on atherogenic 
cholesterol levels as demonstrated by modest improvements in non-HDL-C goal 
attainment.     
Whilst the present data cannot assess whether favourable changes in 
atherogenic particle clearance will translate into better clinical outcomes in patients 
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with T2DM and atherogenic dyslipidaemia, it should be noted that UC failed to 
achieve non-HDL-C <2.59 mmol/L (<100 mg/dL; recommended as a treatment target 
for individuals with T2DM in guidelines4,5) for the majority (82.3%). In contrast, at 
Week 24, only 33.1% of the alirocumab group failed to achieve non-HDL-C 
<2.59 mmol/L (<100 mg/dL). The findings were consistent with previous subgroup or 
post hoc analyses which have reported the effect of PCSK9 inhibitors according to 
mixed dyslipidaemia or diabetes status.18-24 
This study was not designed to assess CV outcomes. Post hoc analyses of 
alirocumab ODYSSEY trials have suggested that event reduction continues to very-
low levels of LDL-C (~25–50 mg/dL);25 however, this requires confirmation in the 
forthcoming ODYSSEY OUTCOMES study, which includes a pre-specified subgroup 
analysis in individuals with diabetes mellitus (DM). CV outcomes data are available 
for other PCSK9 monoclonal antibodies. In the FOURIER study, with individuals with 
CV disease (CVD) with and without T2DM, evolocumab reduced LDL-C by 56 mg/dL 
(~1.4 mmol/L) from baseline with a 20% reduction in major CV events (CV death, MI 
or stroke).26 Similar results were observed in individuals with DM and stable 
ASCVD.11 Among individuals with higher CV risk (46.1–47.8% with DM) a benefit in 
reducing major CV events (nonfatal MI, nonfatal stroke, hospitalization for angina 
requiring revascularization or CV death) was shown with bococizumab (hazard ratio, 
0.79; 95% confidence interval, 0.65 to 0.97; P = .02).27  
Non-HDL-C was chosen as primary endpoint in this study following reports that it 
represents a better risk marker than LDL-C when TGs are elevated.4 However, we 
acknowledge that there is no direct strong evidence from randomized trials that 
additional changes in non-HDL-C, on top of LDL-C reductions, contribute to further 
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CVD reduction. Moreover, it is difficult to separate reductions in non-HDL-C, LDL-C, 
ApoB and LDL particle number, which are highly correlated. There are data from 
meta-analyses suggesting that greater reductions in non-HDL-C and ApoB are 
related to further reductions in CVD28,29, analogous to well-established data for LDL-
C reduction.7,12,26 The importance of reducing atherogenic particle number has 
gained further credence with the large genetic analyses by Ference et al. 
demonstrating that with add-on therapy, which impacts both the quality and content 
of atherogenic particles, any CV benefit is more accurately predicted by particle 
number (as depicted by changes in ApoB) rather than by LDL-C.30 This is supported 
by findings from the recent REVEAL trial with the cholesteryl ester transfer protein  
inhibitor anacetrapib, in which the observed clinical risk reduction was considerably 
less than that anticipated by the observed reductions in LDL-C.31 A meta-regression 
analysis of statin and non-statin therapies by Robinson et al suggested that every 10 
mg/dL reduction in ApoB would result in about a 6% proportional reduction in CVD 
risk.28 Applying those data to the present population with a starting ApoB level of 
about 100 mg/dL, alirocumab, fenofibrate, omega-3 fatty acids and ezetimibe would 
be expected to achieve an absolute reduction of 33.8 mg/dL, 3.8 mg/dL, 1.9 mg/dL 
and 8.8 mg/dL, respectively. Extrapolating from the meta-regression, this would be 
expected to translate into 20.3%, 2.3%, 1.1% and 5.3% reductions in the risk of 
CVD. Of note, the estimated 20.3% risk reduction is consistent with the observed 
results from the FOURIER study,11 and the estimated 5.3% risk reduction is roughly 
consistent with the results of the ezetimibe IMPROVE-IT study.12 Our data also 
suggest that, unless there is some benefit of TG-lowering per se on CVD, as yet 
unidentified and independent of the modest reductions in ApoB and LDL particle 
number, the results of the ongoing outcomes trials for fibrates and fish oils 
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(PROMINENT: NCT03071692; STRENGTH: NCT02104817; REDUCE-IT: 
NCT01492361) are unlikely to show significant CVD risk reduction. Furthermore, 
based on these data there is no rationale for the routine use of fenofibrate as add-on 
to statin therapy if the goal of adding it is to reduce non-HDL-C or ApoB as a means 
to reduce CV risk. 
Statin use has been associated with an increase in risk of T2DM, and mendelian 
randomization studies have reported an association between PCSK9 loss-of-function 
mutations and risk of diabetes.30,32,33 However, we did not see any clinically relevant 
effect of alirocumab on change in glycemic parameters or in use of 
antihyperglycemic agents in this study, supporting previous pooled analyses and 
sub-analyses,22,34,35 and the more recent analysis from the FOURIER study,11,26 
which indicated no meaningful effect of PCSK9 inhibitors on either A1C or FPG 
levels or on rates of new-onset diabetes. However, larger study populations and 
longer-term studies are required to further validate the long-term effects of PCSK9 
inhibition, as these therapies are likely to be continued life-long.  
In this study, alirocumab was generally well tolerated, with comparable rates of 
TEAEs between alirocumab and usual care. No local injection-site reactions (defined 
as those deemed to be allergic and requiring medical consultation) were reported in 
this study in either treatment arm.   
The rate of persistent anti-drug antibodies observed in the present study was 
similar to the overall rate seen in a pooled analysis of 10 ODYSSEY studies, which 
demonstrated substantial LDL-C reductions that were maintained over the course of 
studies, regardless of anti-drug antibody status.36  
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Limitations include the relatively short study duration and number of individuals 
enrolled, which did not allow for analysis of rare adverse events. The awareness of 
treatment might have introduced bias by study participants and investigators.37 
Safety reporting could be influenced as study participants and investigators will know 
what treatment they are receiving. Similarly, treatment adherence to diet and other 
medication may be influenced by the participants’ knowledge about treatment. 
Simultaneous addition of UC therapies was not included in the protocol, although it is 
acknowledged that it may be recommended in real-life practice.  
In conclusion, among individuals with T2DM and mixed dyslipidaemia whose 
total atherogenic cholesterol burden is inadequately controlled despite maximally 
tolerated statin therapy, increasing the clearance of atherogenic lipoproteins with a 
PCSK9 inhibitor more effectively reduces total atherogenic cholesterol levels 
compared with the usual lipid-lowering therapeutic approaches currently utilised. 
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TABLE 1. Baseline characteristics (randomized population) 
 
Alirocumab 75/150 mg Q2W 
(n = 276) 
Usual care  
(n = 137) 
Age (years) 62.8 (9.3) 64.1 (8.8) 
Male 147 (53.3) 69 (50.4) 
Race    
White 247 (89.5) 123 (89.8) 
Black 16 (5.8) 6 (4.4) 
Ethnicity, Hispanic/Latin 35 (12.7) 14 (10.2) 
Body mass index (kg/m2) 32.7 (5.4) 33.2 (4.9) 
A1C (%) 7.1 (0.8) 7.1 (0.9) 
<7% 134 (48.6) 57 (41.6) 
≥7% to <8% 100 (36.2) 56 (40.9) 
≥8% to <9 42 (15.2) 24 (17.5) 
FPG (mmol/L [mg/dL]) 8.04 (2.11) [144.9 (38.1)] 8.22 (2.19) [148.1 (39.4)] 
Duration of DM, years, median 
(Q1:Q3) 
10.7 (5.5:17.5) 11.5 (6.2:18.7) 
Hypertensiona 241 (87.3) 123 (89.8) 
Current cigarette smoker 38 (13.8) 23 (16.8) 
CKDb 41 (14.9) 23 (16.8) 
Individuals with ASCVD 95 (34.4) 47 (34.3) 
Individuals without ASCVD but 
with additional CV risk factor 
181 (65.6) 90 (65.7) 
Any statinc 231 (84.0) 105 (76.6) 
High-intensity statind 107 (46.3) 38 (36.2) 
Moderate-intensity statind 103 (44.6) 64 (61.0) 
Low-intensity statind 21 (9.1) 3 (2.9) 
Any LLT other than statinse 
before randomization 
1 (0.4) 2 (1.5) 
Fenofibrates 1 (0.4) 1 (0.7) 
Cholesterol absorption 0 1 (0.7) 
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inhibitor 
Nutraceuticals impacting 
lipids/other 
0 1 (0.7) 
No LLTc (no statin or other LLT) 44 (16.0) 32 (23.4) 
Statin-intolerant 43 (15.6) 31 (22.6) 
Concomitant antihyperglycemic 
drugsc 
  
Biguanides 211 (76.7) 106 (77.4) 
Insulin 102 (37.1) 56 (40.9) 
Sulfonylureas 67 (24.4) 31 (22.6) 
SGLT2 inhibitors 39 (14.2) 18 (13.1) 
DPP4 inhibitors 36 (13.1) 20 (14.6) 
GLP1-RA 32 (11.6) 21 (15.3) 
Thiazolidinediones 9 (3.3) 5 (3.6) 
Alpha-glucosidase inhibitors 2 (0.7) 2 (1.5) 
Other blood glucose-lowering 
drugs 
9 (3.3) 2 (1.5) 
Baseline lipidsf (mmol/L [mg/dL]) 
Non-HDL-C 4.02 (1.20) [155.1 (46.2)] 4.18 (1.26) [161.5 (48.8)] 
LDL-C, measuredg 2.86 (1.04) [110.4 (40.3)] 3.04 (1.13) [117.3 (43.5)] 
ApoB, mg/dL 101.9 (25.8) 106.1 (28.7) 
Total cholesterol 5.06 (1.19) [195.4 (46.0)] 5.25 (1.32) [202.5 (51.1)] 
Lp(a), median (Q1:Q3), mg/dL 16.0 (5.0:54.0) 15.0 (5.0:40.0) 
TGs, median (Q1:Q3) 2.43 (1.91:3.22)  
[214.5 (169.0:285.0)] 
2.40 (1.90:3.12)  
[212.0 (168.0:276.0)] 
HDL-C 1.04 (0.25) [40.3 (9.8)] 1.06 (0.30) [41.1 (11.6)] 
LDL particle number (nmol/L) 1404.1 (456.1) 1483.8 (482.8) 
ApoA1, mg/dL 138.6 (21.2) 139.4 (22.9) 
LDL particle size, nm 20.3 (0.6) 20.3 (0.6) 
Abbreviations: A1C, glycated hemoglobin; alirocumab 75/150 mg Q2W alirocumab 75 mg Q2W with possible 
dose increase to 150 mg Q2W at Week 12; Apo, apolipoprotein; ASCVD, atherosclerotic cardiovascular disease; 
CKD, chronic kidney disease; CV, cardiovascular; DM, diabetes mellitus; DPP4, dipeptidyl peptidase 4; FPG, 
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fasting plasma glucose; eGFR, estimated glomerular filtration rate; GLP1-RA, glucagon-like peptide receptor 
agonist; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein 
cholesterol; LLT, lipid-lowering therapy; Lp(a), lipoprotein a; non-HDL-C, non-high density lipoprotein cholesterol; 
Q2W, every 2 weeks; Q1/Q3, first/third quartile; SD, standard deviation; SGLT2, sodium-glucose co-transporter 
2; TG, triglyceride.  
aEstablished based on use of antihypertensive medication.  
bDefined as eGFR 15–60 mL/min/1.73m2.  
cData presented for safety population (275 alirocumab; 137 usual care).  
dHigh-intensity statin: atorvastatin 40–80 mg, rosuvastatin 20–40 mg or simvastatin 80 mg. Moderate-intensity 
statin: atorvastatin 10–20 mg, fluvastatin 40 mg, fluvastatin extended release 80 mg, lovastatin 40 mg, 
pitavastatin 2–4 mg, pravastatin 10–20 mg, rosuvastatin 5–10 mg or simvastatin 20–40 mg. Low-intensity statin: 
fluvastatin 20–40 mg, lovastatin 20 mg, pitavastatin 1 mg, pravastatin 10–20 mg or simvastatin 10 mg.  
eIn combination with statins or not.  
fOrder based on hierarchical order, except for LDL particle size.  
gBeta-quantification. 
Data are mean (SD) and n (%). 
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